Table 1.

Patient characteristics

	Overall n = 749 (100%)	No evidence of cancer at biopsy n = 456 (61%)	Gleason score ≤6 PCa n = 137 (18%)	Gleason score ≥7 PCa n = 156 (21%)	p value
Age at biopsy, yr	65 (60–70)	64 (59–68)	64 (60–69)	68 (64–73)	<0.0001
Total PSA	6.3 (4.4–10.7)	5.7 (4.2–8.7)	6.0 (4.4–9.8)	10.2 (5.6–20.3)	<0.0001
Free-to-total PSA ratio	0.17 (0.13–0.22)	0.18 (0.14–0.23)	0.17 (0.13–0.21)	0.14 (0.10–0.18)	<0.0001
Free PSA	1.1 (0.8–1.8)	1.1 (0.7–1.7)	1.1 (0.8–1.7)	1.4 (0.8–2.3)	0.0005
Intact PSA	0.5 (0.3–0.8)	0.5 (0.3–0.7)	0.5 (0.3–0.8)	0.8 (0.4–1.2)	<0.0001
hK2	0.06 (0.04–0.11)	0.06 (0.04–0.09)	0.08 (0.04–0.12)	0.09 (0.06–0.19)	<0.0001
Abnormal DRE	246 (33)	116 (25)	39 (28)	91 (58)	<0.0001
Clinical T stage
T1			98 (72)	64 (41)
T2			34 (25)	47 (30)
T3			5 (3.6)	42 (27)
T4			0 (0)	2 (1.3)
Unknown			0 (0)	1 (0.6)

DRE = digital rectal examination; hK2 = human kallikrein-related peptidase 2; PCa = prostate cancer; PSA = prostate-specific antigen.

All values are median (interquartile range) or frequency (%).